by Karen O'Hanlon Cohrt | Apr 4, 2023 | Disease Models
This article was originally published on 4th April 2023. It was revised and republished on 19th March 2023, to reflect important updates in the NASH therapeutic development space, including FDA approval of Rezdiffra in March 2024. Welcome to our new mini-series about...
by Karen O'Hanlon Cohrt | Dec 26, 2023 | Disease Models
It’s a fibroblast-like cell adorned with long cytoplasmic processes that wrap around the endothelial cells in blood vessels, it controls blood flow through the blood vessels, and it is essential for normal brain function and development. Which cell type is it? Well,...
by Olwen Reina | Jul 26, 2016 | Disease Models
Melanocytes are cells that produce melanin, the pigment present in our skin, eyes, and hair. iPS-derived melanocytes are used in models of skin disease, drug toxicity assays, skin bioprinting and in cell therapy R&D. Previously, we looked at the role of melanin...
by Karen O'Hanlon Cohrt | Nov 21, 2023 | Industry News, Trends
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and cancerous cells, ADCs are...
by Karen O'Hanlon Cohrt | Nov 18, 2022 | Trends
Welcome to our new blog series about the blood brain barrier (BBB)! In Part 1, we will give a brief history on the discovery of the BBB, as well as introduce what we know about its composition and biological functions. The blood brain barrier or BBB is a highly...
